
    
      Evaluation of the safety and tolerability of escalating doses of NR1 administered
      intracerebrally at a single time-point post-injury to subjects with chronic ISS with or
      without cortical stroke. The study will be a dose escalation using up to 4 cohorts each at a
      single dose level, of intracerebral administration of NR1 cells. Secondary objectives are to
      evaluate clinical and radiologic responses as well as utility of efficacy measurement tools.
    
  